Revelation Biosciences, Inc. (REVB)
- Previous Close
2.0900 - Open
1.4500 - Bid 1.2300 x 100
- Ask 1.3400 x 200
- Day's Range
1.2600 - 1.5200 - 52 Week Range
0.8100 - 28.2000 - Volume
2,319,871 - Avg. Volume
2,068,958 - Market Cap (intraday)
2.136M - Beta (5Y Monthly) 0.22
- PE Ratio (TTM)
-- - EPS (TTM)
-33.1800 - Earnings Date Nov 7, 2024 - Nov 11, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
16.95
Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was founded in 2020 and is based in San Diego, California.
www.revbiosciences.comRecent News: REVB
View MoreResearch Reports: REVB
View MorePerformance Overview: REVB
Trailing total returns as of 8/22/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: REVB
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: REVB
View MoreValuation Measures
Market Cap
3.43M
Enterprise Value
9.66M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
3.01
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-42.07%
Return on Equity (ttm)
-253.32%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-15.9M
Diluted EPS (ttm)
-33.1800
Balance Sheet and Cash Flow
Total Cash (mrq)
12.07M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
834.4k